Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy rises as it obtains international quality standard for LIGHT system

ISO 13485:2016 is an international quality standard that ensures the consistent design, development, production, installation and sale of medical devices
Protons about to collide
The LIGHT system uses a proton beam to treat tumours in patients

Advanced Oncotherapy PLC (LON:AVO) shares rose in mid-morning trading Monday after it received a quality standard certification for its LIGHT proton therapy system following an audit by compliance firm Lloyd’s Register.

ISO 13485:2016 is an internationally recognised quality standard that ensures the consistent design, development, production, installation and sale of medical devices that are safe for their intended purposes.

READ: Advanced Oncotherapy raises £10mln at a premium

The company said the certification was an important milestone that would allow it to continue developing its LIGHT system in compliance with the highest safety and product performance standards.

It would also allow it to make the product available for patient treatment once the medical device file had been approved.

The LIGHT system is focused on the use of protons, small sub-atomic particles, to treat tumour growths in patients using an accelerator beam similar to that of linear x-rays currently used in cancer treatment.

AVO is currently focused on increasing the power of the LIGHT proton beam to 230 mega-electron volts, the level required to treat deep-seated tumours in patients.

Dr Michel Baelen, the company’s director of regulatory affairs, said the compliance with the quality standard illustrated the importance the firm placed on the quality of its product, as well as “dedication to ensuring that the infrastructure to develop and manufacture our product is safe, effective and reliable”.

AVO shares were up 1.3% at 39p.

--Adds share price--

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

Article
September 28 2018

Related Articles

pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use